# Topotecan

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/topotecan
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, TPT, Hycamtin, NSC-609699, SKF S-104864-A, topotecan hydrochloride, 9-dimethylaminomethyl-10-hydroxycamptothecin

## Overview

Topotecan is a semisynthetic camptothecin derivative that functions as a topoisomerase I inhibitor, trapping the topoisomerase I-DNA cleavable complex to prevent religation of DNA strand breaks. This mechanism selectively targets rapidly dividing cancer cells, making topotecan an FDA-approved chemotherapy agent for ovarian, cervical, and small cell lung cancers.

## Health Benefits

• Approved for ovarian cancer treatment as a topoisomerase I inhibitor (evidence quality not specified in available research)
• Inhibits DNA replication in rapidly dividing cells by stabilizing topoisomerase I-DNA complexes (mechanism established)
• Water-soluble formulation improves bioavailability compared to parent compound camptothecin
• Clinical use established for various malignancies (specific trial evidence not provided)
• Targets cancer cells during active replication phase through DNA damage induction

## Mechanism of Action

Topotecan binds to and stabilizes the covalent topoisomerase I-DNA cleavable complex, preventing the enzyme from religating single-strand DNA breaks it has introduced during replication. This trapped ternary complex collides with advancing replication forks, converting reversible single-strand breaks into irreversible double-strand breaks that trigger apoptosis. Topotecan's lactone form (the active moiety) preferentially accumulates in the nucleus at physiologic pH, while the open-chain carboxylate form predominates in plasma and binds albumin, reducing bioavailability at target sites.

## Clinical Summary

FDA approval for recurrent ovarian cancer was supported by a pivotal Phase III trial comparing topotecan to paclitaxel, showing a comparable overall response rate of approximately 20% with a median overall survival of 61 weeks in the topotecan arm. In small cell lung cancer, a Phase III trial (n=211) demonstrated topotecan's non-inferiority to CAV (cyclophosphamide, doxorubicin, vincristine) combination therapy in previously treated patients, with an objective response rate of 24.3%. For cervical cancer, GOG 0179 (n=294) showed that topotecan plus cisplatin significantly improved overall survival compared to cisplatin alone (9.4 vs. 6.5 months; p=0.017). Evidence quality is generally moderate, with most pivotal trials being open-label and limited by small sample sizes in specific subpopulations.

## Nutritional Profile

Topotecan is a synthetic chemotherapeutic compound (semisynthetic derivative of camptothecin), not a food or nutritional substance. It contains no macronutrients (zero protein, fat, carbohydrates, or fiber), no dietary vitamins, and no dietary minerals. Molecular formula: C23H23N3O5; molecular weight: 421.45 g/mol. The active moiety is a lactone ring structure (E-ring) that must remain intact for cytotoxic activity; at physiological pH (~7.4), approximately 50% converts to the inactive open-ring carboxylate form, reducing effective bioavailability. Administered as topotecan hydrochloride (IV formulation: 4 mg/4 mL vial at 1 mg/mL concentration; oral capsule formulation: 0.25 mg and 1 mg capsules with approximately 40% oral bioavailability). The compound contains a hydroxyl group, a basic dimethylaminomethyl substituent, and a quinoline core as primary bioactive structural features. Plasma protein binding is approximately 35%. No dietary fiber, phytonutrients, [antioxidant](/ingredients/condition/antioxidant)s, or caloric content is present. The compound is clinically dosed at 1.5 mg/m²/day IV or 2.3 mg/m²/day orally, not in nutritional quantities. Bioavailability is pH-dependent and influenced by ABCG2 (BCRP) transporter-mediated efflux, which can reduce intestinal absorption.

## Dosage & Preparation

No clinically studied dosage ranges for topotecan in extract, powder, or standardized forms are provided in the available research. The compound is administered clinically as hydrochloride salt in injectable or oral formulations, but specific dosing details are not included. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

The most clinically significant adverse effect of topotecan is severe myelosuppression, with grade 3–4 neutropenia occurring in up to 80% of patients, often requiring G-CSF support or dose reduction to the standard 1.5 mg/m² IV daily for 5 days per 21-day cycle. Topotecan is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP); concurrent use of inhibitors such as elacridar or cyclosporine significantly increases systemic exposure and toxicity risk. It is classified as FDA Pregnancy Category D, with evidence of fetal harm in animal studies, and is contraindicated in patients with severe bone marrow depression or baseline neutrophil counts below 1,500 cells/mm³. Patients with renal impairment (CrCl 20–39 mL/min) require dose reduction to 0.75 mg/m², as approximately 30% of the drug is renally excreted unchanged.

## Scientific Research

The research dossier lacks specific clinical trial details, PMIDs, or meta-analyses for topotecan. While its approval for ovarian cancer and mechanism as a topoisomerase inhibitor are confirmed, comprehensive clinical evidence including study designs, sample sizes, and outcomes are not available in the provided research.

## Historical & Cultural Context

Topotecan itself has no traditional medicinal use as it is a modern semisynthetic derivative developed in the late 20th century. The parent compound camptothecin comes from Camptotheca acuminata, known as 'Xi Shu' in traditional Chinese medicine, where it was used for its purported anticancer properties.

## Synergistic Combinations

Not applicable - topotecan is a prescription chemotherapy drug not suitable for supplement stacking

## Frequently Asked Questions

### What cancers is topotecan approved to treat?

Topotecan has FDA approval for three indications: relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response, recurrent ovarian carcinoma after initial platinum-based therapy, and cervical cancer in combination with cisplatin for stage IVB or recurrent disease. An oral formulation is specifically approved for SCLC, offering an alternative to intravenous administration for eligible patients.

### How does topotecan differ from irinotecan?

Both topotecan and irinotecan are camptothecin derivatives that inhibit topoisomerase I, but irinotecan is a prodrug that must be converted to its active metabolite SN-38 by carboxylesterase enzymes in the liver and tumor tissue, making its pharmacokinetics more variable. Topotecan is active as administered (after pH-dependent lactone-carboxylate equilibration) and is primarily renally cleared, while SN-38 undergoes UGT1A1-mediated glucuronidation, meaning patients with UGT1A1*28 polymorphisms face elevated irinotecan toxicity risk that does not apply to topotecan.

### What is the standard topotecan dosage for ovarian cancer?

The standard intravenous dosing regimen for recurrent ovarian cancer is 1.5 mg/m² administered by 30-minute infusion on days 1 through 5 of a 21-day cycle. Dose reductions to 1.25 mg/m² are recommended if grade 4 neutropenia lasts more than 7 days or if grade 4 thrombocytopenia occurs; patients with CrCl 20–39 mL/min should receive a reduced dose of 0.75 mg/m² to account for impaired renal clearance of the active lactone form.

### Why is topotecan's water solubility clinically important?

Topotecan's water solubility is a key pharmacokinetic advantage over its parent compound camptothecin, which had erratic absorption and severe toxicity in early trials partly due to its poor aqueous solubility. The water-soluble formulation allows reliable intravenous delivery and also enabled development of an oral capsule formulation, which achieves approximately 40% bioavailability and allows outpatient dosing for small cell lung cancer patients who prefer or require non-infusion treatment.

### What are the most serious side effects of topotecan chemotherapy?

Myelosuppression is the dose-limiting toxicity of topotecan: grade 3–4 neutropenia occurs in roughly 78–80% of patients on the standard 5-day IV regimen, grade 3–4 thrombocytopenia in approximately 27%, and grade 3–4 anemia in about 37%, often necessitating transfusions or growth factor support. Non-hematologic toxicities include nausea (64%), vomiting (45%), alopecia, and fatigue, and there is a risk of interstitial lung disease, though this is rare; febrile neutropenia carries mortality risk and typically requires hospitalization and IV antibiotics.

### What is the mechanism of action that makes topotecan effective against cancer cells?

Topotecan works as a topoisomerase I inhibitor by stabilizing the complex between the topoisomerase I enzyme and DNA, preventing the enzyme from completing its normal function of unwinding DNA during replication. This stabilization causes DNA breaks in rapidly dividing cancer cells, triggering cell death while cancer cells are actively replicating. Normal cells divide more slowly and are therefore less susceptible to topotecan's effects, providing some selectivity for cancer treatment.

### Why is topotecan formulated as a water-soluble compound rather than using the parent compound camptothecin?

Topotecan's water-soluble formulation was developed to overcome the poor bioavailability and solubility limitations of the parent compound camptothecin, making it suitable for intravenous administration in clinical practice. The improved water solubility allows for better drug delivery to tumor sites and more consistent plasma concentrations compared to camptothecin. This formulation enhancement was essential for topotecan to become a viable chemotherapy agent that could be reliably dosed in cancer patients.

### Which patient populations are most appropriate candidates for topotecan treatment?

Topotecan is most appropriate for patients with advanced or recurrent ovarian cancer, small cell lung cancer, and certain other solid tumors who have adequate bone marrow, kidney, and liver function to tolerate the medication. Patients must have sufficient performance status to withstand chemotherapy's systemic effects and be able to receive close medical monitoring during treatment. Elderly patients and those with significant organ impairment may require dose adjustments or alternative therapies due to increased risk of severe toxicity.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*